China Asthma Drug Market Report

The Chinese Asthma Drug Drug Utilization

Publication Date	May 2009
Publisher	Draco Healthcare Cons.
Product Type	Report
Pages	103
ISBN Number	not applicable
Product Code	DHC00011

Buy this product or for assistance call +44 20 7060 7474

PDF £2,705.00$4500 | €3028

PRINT £3,005.00$4999 | €3363

CD-ROM £2,705.00$4500 | €3028

FAX Order above formats by FAX

Summary

According to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide. One out of every 250 disease-related deaths was caused by asthma. In China, the incidence rate of asthma patients has continuously increased in the recent years, especially among urban children. The latest survey shows that the incidence rate is 0.7% - 1.5% in adults and 0.11% - 2.03% in children. Asthma has been known as a costly disease that is difficult to cure. On average asthma treatment will cost a patient over RMB 3000 per year in China. Assuming a national asthma population of 15 - 18 million and a 10% treatment rate, the cost of asthma treatment will be RMB 4.5 - 5.6 billion.

The Chinese asthma drug market reached RMB 1.7 billion in 1999. In 2007, asthma drug sales were RMB 4.855 billion (USD 714 million), an increase of 22.14% from 2006 This report has systemically analyzed the Chinese asthma drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA).

Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions. Market shares from all major players including multinational and Chinese pharmaceutical companies and their major asthma products are analyzed systemically based on data from significant number of Chinese hospitals.

The comprehensive hospital utilization data of major asthma drugs will present you a clear picture of the competition landscape of Chinese asthma drug market and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market. This China Asthma Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies.

These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.

Content

Chapter I. Clinical Application of Asthma Drugs
- Section 1. Definition of Asthma
- 1.1 Definition
- 1.2 The Relationship of Asthma Airway Pathology and Impaired Pulmonary Function
- Section 2. Risk Factors of Asthma
- Section 3. Diagnosis and Classification of Asthma
- 3.1 Diagnosis of Asthma
- 3.2 Classification of Asthma
- Section 4. Treatment of Asthma
- 4.1 Management Plans Are Based on Asthma Control Levels
- 4.2 New Status of Certain Asthma Drugs
- 4.3 Dose Reduction for Maintenance Therapy
- Section 5. Common Asthma Drugs
- 5.1 Glucocorticoids Drugs
- 5.2 Theophylline Drugs
- 5.3 B-2 Receptor Agonists
- 5.4 The M-receptor Blockers
- 5.5 a-receptor Blocker
- 5.6 Anti-allergic Drugs
- 5.6.1 The H1 receptor blocker
- 5.6.2 Anaphylactic Mediator Blockers
- 5.6.3 Leukotriene-interfering Drugs
- 5.7 Antibiotics
- 5.8 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- 5.9 Diuretics
- 5.10 Other Inflammatory Mediator Antagonists and Cytokine Antagonists
- 5.11 Marrow Acidophil Progenitor Cell Inhibitors
- 5.12 Allergen Specific Immunotherapy (AIT)
- 5.13 Gene Therapy
Chapter II. Analysis of the Chinese Asthma Drug Market
- Section 1. Market Size of the Chinese Asthma Drug Hospital Market
- 1.1 Epidemiology of Asthma in China
- 1.2 Theoretical Size of the Asthma Drug Market in China
- 1.3 Market Sizes and Annual Growth Rates of the Actual Asthma Drug Market in China (2003-2007)
- Section 2. Market Shares of the Top 20 Asthma Drugs in China (2005-2007)
- Section 3. Market Shares of Top 20 Pharmaceutical Companies in the China's Asthma Drug Market (2005-2007)
- Section 4. Annual Growths of Market Shares of Top 20 Asthma Drugs in China (2005-2007)
- Section 5. Market Potential of the Top 20 Asthma Drugs
Chapter III. Analysis of Brand Asthma Drugs in China
- Section 1: Market Shares of the Top 10 Branded Asthma Drugs in China
- Section 2: Major Manufacturers of Asthma Drugs and Their Key Products in China
- GSK
- AstraZeneca
- Merck
- Boehringer Ingelheim
- Sankyo
- Heilongjiang Fuhe Huaxing
- Otsuka Pharmaceutical Ltd
Chapter IV. R&D of Asthma Drugs
- Section 1. Conventional Medicines
- 1.1 Glucocorticoids
- 1.2 B-2 Receptor Agonist
- 1.3 M-receptor Blocking Agent
- 1.4 Theocin Category
- 1.5 Anti-leukotrienes medicine
- 1.6 Cromolyn sodium category
- 1.7 Antihistamine
- Section 2. Non-conventional Medicines
- Section 3. Immunotherapy
- 3.1 Specific Immunity Treatment (SIT)
- 3.2 BCG Vaccine (Bacillus Calmette-Guerin)
- 3.3 IL-4 and IL-5 Inhibitors
- 3.4 Anti-IgE Therapy
- 3.5 Neurokinin (NK) Receptor Antagonist
- 3.6 Others
- Section 4. Gene Therapy
- Section 5. Chinese Medicine Treatment
- Section 6. Other Therapies
Chapter V. Brand Names, Manufacturers, and Formulas of Asthma Drugs in China
- Section 1. Brand Names, Chemical Names, Manufacturers and Formulas of Asthma Drugs in China
Chapter VI. Prices of Asthma Drugs, and Asthma Drugs on the Chinese National Healthcare Insurance List
- Section 1: Formulas, Packages, Retail prices, Manufacturers (for Branded Drugs only) of Asthma Drugs in China
- Section 2. Asthma Drugs on the Chinese National Healthcare Insurance List
- 2.1. Chemical Drugs on the National Healthcare Insurance List
- 2.2. Traditional Chinese Medicines (TCMs) on the National Healthcare Insurance List
List of Tables
- Table 1. Classification of Asthma Prior to Treatme
- Table 2. Control Levels of Asthma
- Table 3. Market Shares of Top 20 Asthma Drugs in China 2005-2007
- Table 4. Annual Sales of Top 20 Asthma Drugs in China 2005-2007
- Table 5. Market Shares of the Top 20 Manufacturers of Asthma Drugs 2005-2007
- Table 6. Sales of Asthma Drugs from the Top 20 Manufacturers 2005-2007
- Table 7. Sales Growth of the Top 20 Asthma Drugs 2006-2007
- Table 8. Market Shares of GSK Brand Asthma drugs in the Chinese Hospital Market 2003-2007
- Table 9. Sales of GSK Brand Asthma drugs in the Chinese Hospital Market 2003-2007
- Table 10. Branded Asthma Drugs by AstraZeneca
- Table 11. Market Shares of AstraZeneca Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 12. Sales of AstraZeneca Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 13. Market Shares of Merck Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 14. Sales of Merck Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 15. Market Shares of Boehringer Ingelheim Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 16. Sales of Merck Boehringer Ingelheim Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 17. Market Shares of Sankyo Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 18. Sales of Sankyo Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 19. Market Shares of Fuhe Huaxing Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 20. Sales of Fuhe Huaxing Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 21. Market Shares of Otsuka Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 22. Market Shares of Otsuka Brand Asthma Drugs in the Chinese Hospital Market 2003-2007
- Table 23. Brand Names, Chemical Names, Manufacturers and Formulas of Asthma Drugs in China
- Table 24. Formulas, Packages, Retail prices, Manufacturers (for Branded Drugs only) of Asthma Drugs in China
- Table 25. Chemical Drugs on the Chinese National Healthcare Insurance List
- Table 26. Traditional Chinese Medicines (TCMs) on the National Healthcare Insurance List
List of Figures
- Figure 1. Asthma Management Map
- Figure 2. Market Sizes of the Chinese Asthma Drug Market (2003-2007)
- Figure 3. Market Potentials of the Top Asthma Drugs, China, 2007
- Figure 4. Market Shares of the Top 10 Asthma Drugs 2006
- Figure 5. Market Shares of the Top 10 Asthma Drugs 2007
- Figure 6. Sales of GSK Asthma Drugs 2005, 2006 and 2007
- Figure 7. Sales of Branded Asthma Drugs from AstraZeneca 2005, 2006 and 2007
Top 20 Pharmaceutical Companies in the Chinese Asthma Drug Hospital Market (at least > 0.53% of the total Chinese Asthma Drug Hospital Market)
- Boehringer Ingelheim
- Zhejiang Beisheng
- AstraZenaca
- GSK
- Guangdong Huanqiu
- Guangzhou Maite-Xinghua
- Guilin Nanyao
- Hangzhou MSD China
- Heilongjiang Fuhe Huaxing
- Henan Kaifeng Kangnuo
- Hengyang Hengsheng
- Jiangsu China Medicine and Technology University
- Otsuka Pharmaceutical Co Ltd
- Qingzhou Yaowang
- Sankyo
- Shandong Hualu
- Shandong Ruiyang
- Shanghai Ethypharm
- Sichuan Chengdu Huayu
- Zhejiang Changxing